We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Scholar Rock Holding Corp
4 own
8 watching
Current Price
$7.1
$-0.19
(-2.61%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
493.53M
52-Week High
13.00000
52-Week Low
5.56000
Average Volume
0.25M
Dividend Yield
--
P/E Ratio
--
Market Capitalization493.53M52-Week High13.0000052-Week Low5.56000Average Volume0.25MDividend Yield--P/E Ratio--What does the Scholar Rock Holding Corp do?
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients suffering from a range of serious diseases, including neuromuscular disorders, cancer, and fibrosis. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.
Read More
How much money does Scholar Rock Holding Corp make?
News & Events about Scholar Rock Holding Corp.
Business Wire
3 months ago
Scholar Rock (NASDAQ: SRRK), a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced...
Business Wire
5 months ago
Scholar Rock (NASDAQ: SRRK; The Company), a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that the Company granted inducement equity awards covering an aggregate of 83,125...
Zolmax
6 months ago
Scholar Rock Holding Co. (NASDAQ:SRRK Get Rating) Analysts at Wedbush issued their Q1 2024 earnings per share estimates for shares of Scholar Rock in a research note issued to investors on Tuesday, March 7th. Wedbush analyst D. Nierengarten anticipates that the company will earn ($0.67) per share ...
Business Wire
7 months ago
Scholar Rock (NASDAQ: SRRK; The Company), a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that the Company granted inducement equity awards covering an aggregate of 285,000...
Ticker Report
8 months ago
Scholar Rock Holding Co. (NASDAQ:SRRK Get Rating) major shareholder Public Equities L.P. Invus bought 48,774 shares of the companys stock in a transaction that occurred on Thursday, January 5th. The shares were bought at an average cost of $9.33 per share, for a total transaction of $...
Frequently Asked Questions
Frequently Asked Questions
What is Scholar Rock Holding Corp share price today?
Can Indians buy Scholar Rock Holding Corp shares?
How can I buy Scholar Rock Holding Corp shares from India?
Can Fractional shares of Scholar Rock Holding Corp be purchased?
What are the documents required to start investing in Scholar Rock Holding Corp stocks?
What is today’s traded volume of Scholar Rock Holding Corp?
What is today’s market capitalisation of Scholar Rock Holding Corp?
What is the 52-Week High and Low Range of Scholar Rock Holding Corp?
What percentage is Scholar Rock Holding Corp down from its 52-Week High?
What percentage is Scholar Rock Holding Corp up from its 52-Week Low?
Current Price
$7.1
$-0.19
(-2.61%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.